# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹74 Cr** Q4 (+22% YoY) · **₹277.9 Cr** FY26 (+16.2% YoY) * **Gross Margin:** **70.5%** Q4 Consolidated · **~76%** Core Dental Business * **EBITDA:** **₹13.5 Cr** Q4 (+41.8% YoY) · **₹43.4 Cr** FY26 (15.6% Margin) * **Adjusted EBITDA:** **₹13.1 Cr** Q4 · **₹51.1 Cr** FY26 * **PAT:** **₹10.1 Cr** Q4 (+135% YoY) · **₹28.9 Cr** FY26 (10.4% Margin) * **Cash & Investments:** **~₹99 Cr** ## B. Revenue Growth * **Record Quarterly Performance:** Achieved highest-ever quarterly top-line results in Q4, marking a strong recovery from a softer third quarter. * **Diversified Monetization:** Revenue streams are anchored by initial hardware sales (scopes) complemented by a recurring subscription point system for clinical evaluations. * **Market Resilience:** Delivered double-digit annual growth despite macroeconomic headwinds and regional competition. ## C. Margin Expansion * **Operating Leverage:** Significant margin expansion driven by stable gross margins and disciplined cost management as the business scales. * **Product Mix Impact:** Consolidated margins reflect the dilutive effect of lower-margin scanner sales; however, the core dental segment remains highly profitable and stable. * **Efficiency Outlook:** Management anticipates disproportionately slower growth in personnel costs due to aggressive investments in **automation and digital dentistry**. ## D. Profitability Metrics * **Earnings Momentum:** Profit Before Tax (PBT) nearly doubled in the final quarter, contributing to a robust **40%** annual growth in pre-tax earnings. * **Expense Optimization:** Bottom-line performance was supported by a reduction in other expenses and a specific **₹91 lakh** Expected Credit Loss (ECL) credit. * **Strategic Validation:** Management cites increased prescription volumes and positive clinical intent as evidence that current strategic initiatives are gaining traction. ## E. Balance Sheet * **Fortress Balance Sheet:** Maintained a debt-free status with a substantial cash reserve to fund strategic deployments and defend market share against funded competitors. * **Capital Allocation:** Executed **₹18.4 Cr** in CAPEX during the fiscal year while benefiting from a one-time **₹1.3 Cr** tax adjustment related to gratuity. --- # 2. Segment & Product Performance ## A. Key Figures * **Dental Lab Revenue:** **₹45.9 Cr** Total (+27% YoY) · **₹23.7 Cr** Domestic (+16.3% YoY) * **Bizdent Aligner Growth:** **10.9%** YoY * **Vedia Revenue:** **₹7.3 Cr** ## B. Dental Lab Performance * **Record Top-line Momentum:** Achieved highest-ever quarterly revenue and a steady run rate of **₹40-45 Cr**, fueled by a recovery in India and record-breaking international contributions. * **Structural Tailwinds:** Domestic growth is being catalyzed by ongoing industry consolidation, the integration of AI innovations, and a tightening regulatory environment. * **Geographic Mix:** The international segment is currently outperforming domestic operations, shifting the division's growth profile toward global markets. ## C. Bizdent Aligners * **Margin-First Strategy:** Revenue remained relatively flat between FY25 and FY26 as management intentionally prioritized profitability over volume in response to intense domestic pricing pressure. * **Recovery & Outlook:** The brand showed a meaningful sequential recovery in Q4; management remains bullish on the "invisible aligner" category due to rising global awareness and value-added service opportunities. ## D. Vedia & Kids-e-Dental * **Vedia Stability:** Raw material revenue remained stable sequentially, though March performance was dampened by **higher freight costs** and global logistical uncertainties. * **Export Dynamics:** Vedia continues to supply high-growth external customers in export markets while management evaluates pricing normalization and necessary regulatory approvals for further scaling. * **Pediatric Contribution:** Kids-e-Dental maintained a steady contribution to the specialized dental portfolio. --- # 3. Technology & Innovation ## A. Key Figures * **Digital Impression Penetration:** **80%** Current domestic lab business () · **>90%** Medium-term target () * iScope 360 Scan Speed: **within a minute** for full intraoral scan via smartphone, with oral health assessment in about two minutes ## B. iScope 360 Launch * **First-to-Market Advantage:** Launched India’s first AI-connected remote dental platform, positioning the firm as a pioneer in remote aligner monitoring to drive segment momentum. * **Comprehensive Service Bouquet:** The platform integrates aligner monitoring, oral health screening, and live consultations, claiming a more robust feature set than existing **US or European** alternatives. * **Hardware Versatility:** The handheld intraoral scope is compatible with any smartphone, enabling instant detection of clinical issues like plaque and cavities from remote locations. ## C. Digital Penetration & AI Strategy * **Digitization as Growth Engine:** High existing digital adoption serves as a long-term revenue driver; strategy focuses on scanner sales and **AI dent** investments to enhance automation. * **Operational Efficiency:** Transitioning toward a near-total digital threshold for crowns, bridges, and aligners to optimize laboratory workflows and competitive positioning. ## D. Remote Monitoring & Ecosystem * **Patient Accessibility:** Targeted at reducing clinic visit frequency for diverse groups, including **NRI patients and foreign tourists**, thereby improving treatment compliance. * **Closed Ecosystem Security:** Ensures dentist-patient continuity via a QR-coded invitation system, preventing patient leakage and maintaining the dentist as the primary point of contact. * **Monetization Flexibility:** Provides practitioners with discretionary billing models, allowing the tool to be used as a premium subscription service or a value-add for high-ticket procedures. --- # 4. Geography & Market Mix ## A. Key Figures * **Export Revenue Share:** **33%-34%** of total revenue * **US Market Contribution:** **20%** of total revenue * **International Lab Growth:** **40.9%** YoY * **Dentist Network:** **22,000** total practitioners · **5,000–7,000** aligner-specific practitioners ## B. Domestic Recovery & Expansion * **Broad-Based Rebound:** Q4 FY '26 marked a recovery period characterized by disciplined execution and segment-wide performance improvements. * **Vast Addressable Market:** Significant headroom for domestic growth remains, as current reach covers only a small fraction of India’s **300,000** practicing dentists. ## C. US Export & DSO Strategy * **Resilient US Outlook:** Despite absorbing **higher tariff costs** early in the quarter, the US business environment has improved significantly; management anticipates no long-term growth impediments. * **Strategic DSO Partnerships:** Revenue is anchored by major partners like **Heartland Dental**, yet remains highly diversified to mitigate single-client dependency. * **Portfolio Scaling:** Active plans are underway to integrate additional Dental Support Organizations (DSOs) to sustain export momentum. ## D. Global Expansion & Material Business * **International Profitability:** Robust double-digit growth in international labs was achieved despite global uncertainties and trade-related headwinds. * **Distributor Network:** The material business spans **30 to 50 countries**, strategically utilizing distributors to target orthodontists without competing against the in-house aligner brand. * **Platform Evolution:** The B2B2C model, currently operational in India, is being evaluated for global export to further scale the digital platform. --- # 5. Strategic Initiatives ## A. Key Figures * **Scanner Sales Volume:** **211 units** current quarter · **1,009 units** annual total * **Device Retail Price:** **₹2,000** approx. per unit * **Historical CAPEX:** **₹18 Cr** previous year ## B. Scanner Deployment Strategy * **Digital Growth Enabler:** Rapid scanner deployment serves as a strategic catalyst for the laboratory and aligner segments, as digital-integrated dentists yield superior growth and revenue profiles. * **Market Pre-emption:** Management is prioritizing aggressive unit placement to capture market share before the hardware evolves into a low-margin commodity business. ## C. Branding & Distribution * **Professional-Led Model:** Current strategy leverages the "dentist-patient trust factor" for distribution; B2C or pharmacy retail remains a future consideration only after a **1-2 year** period of dentist-led patient education. * **Brand Identity:** The company is consolidating its market presence under the **"Illusion"** brand (Aligners and Dental), moving away from corporate-name recognition to drive professional accessibility. ## D. Capital Allocation & M&A * **Future Investment:** FY27 CAPEX will be funded via remaining **IPO proceeds**, with deployment scaled to match operational capacity and top-line momentum. * **Dynamic Resource Management:** Resource allocation between domestic and export markets is driven by real-time macro dynamics rather than fixed percentage targets. * **Inorganic Growth:** Management remains open to strategic acquisitions, mergers, or IP investments specifically within the aligner space to drive market consolidation. --- # 6. Risks & Healthcare Macro ## A. Key Figures * **US Export Tariff:** **10%** Current Rate (vs. **50%** historical peak) * **International Margin Impact:** **74 bps** EBITDA reduction due to US tariffs * **Logistics Inflation:** **2x to 3x** increase in freight costs for Vedia ## B. US Tariff Volatility & Geopolitics * **Manageable Tariff Environment:** Current duty rates are viewed as sustainable compared to historical highs, though they contributed to a slight contraction in international margins. * **Strategic Diversification:** Management is actively expanding into non-US global geographies to mitigate geopolitical risks and domestic aligner competition. * **Partner Uncertainty:** Ongoing tariff volatility has prompted contract renewal inquiries and reviews from major partners, including **Heartland Dental**. * **Operational Resilience:** Despite labor code transitions and external headwinds, the company maintained record annual results and organizational stability. ## C. Regulatory Approvals * **Market Expansion Pipeline:** International registrations for **Kids-e-Dental** and **Pediatric Dental** are in progress to unlock EU and U.S. revenue streams. * **Timeline Uncertainty:** While preliminary registration steps are cleared, management remains cautious on specific guidance due to the unpredictable nature of regulatory bodies. ## D. Freight Costs * **Logistical Headwinds:** Sharp spikes in shipping costs delayed Q4 shipments for Vedia, though management views this as a transient issue rather than a structural risk. --- # 7. Guidance & Outlook ## A. Key Figures * **Target EBITDA Margin:** **18% to 20%** by FY27/FY28 * **Target Gross Margin:** **75% to 80%** by FY27/FY28 * **Target PAT Margin:** **13% to 15%** by FY27/FY28 * **Historical Growth Context:** **24%** (two years ago) · **16%** (most recent fiscal) ## B. FY27 Projections * **Profitability Roadmap:** Management expects to sustain or enhance current profitability through operational leverage as the business scales toward its long-term margin targets. * **Recovery Trajectory:** Leadership views recent quarterly volatility as an anomaly, expressing confidence in returning to historical growth levels barring macroeconomic shifts. ## C. Growth Trajectory * **Structural Tailwinds:** Long-term optimism is anchored in India’s under-penetrated dental sector and a rapid industry-wide transition toward **digital dentistry**. * **Material Business Scaling:** Following a **6 to 7 year** development phase, the material segment is now entering international markets with significant expansion expected over the next **2 to 3 years**. * **Omnichannel Momentum:** Strong performance in the most recent quarter supports a positive multi-year outlook for both domestic and international dental lab operations. * **Growth Consistency:** The company aims to replicate its historical double-digit growth trajectory over the next **two to three years**, leveraging its established market position.